Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Neprilysin on Glucagon-like Peptide-1

Trial Profile

The Effects of Neprilysin on Glucagon-like Peptide-1

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Sitagliptin
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Jun 2019 Results hypothesizing that Sacubitril/Valsartan attenuates neprilysin-dependent degradation of GLP-1, and has synergistic effects when combined with Sitagliptin using two open labeled trials presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 14 May 2019 Status changed from recruiting to completed.
    • 10 May 2019 Results investigating whether inhibition of neprilysin by sacubitril/valsartan alone (study 1) or in combination with a DPP-4 inhibitor (sitagliptin) (study 2) increases postprandial plasma concentrations of biologically active GLP-1 in healthy young men published in the Journal of Clinical Endocrinology and Metabolism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top